Thrombotic Microangiopathy During Pregnancy: Role of Soluble Fms-like Tyrosine Kinase-1–Placental Growth Factor Ratios Thrombotic microangiopathies (TMAs) are severe endotheliopathies that can arise in pregnancy and require early recognition. Complement-mediated (C-)TMA should be differentiated from other endotheliopathies of pregnancy, as treatment differs. Here, we report on a case of a pregnant woman with acute kidney injury requiring hemodialysis due to C-TMA on the background of a pathogenic C3 variant at 28+5 weeks of gestation. Low soluble Fms-like tyrosine kinase-1 to placental growth factor (sFlt1/PlGF) ratio excluded preeclampsia.
https://www.ajkd.org/article/S....0272-6386(25)01170-9

In Reply to “Low-Flow Home Hemodialysis Technologies: The Key to Greener Dialysis?” We read with interest Cuadrado-Payan et al.’s letter on the potential environmental benefits of newer haemodialysis systems (NxStage System One®, Physidia S3®, Tablo®, DIMI®) compared with conventional machines. Because these devices are designed to operate at lower dialysate flows, we agree they can reduce dialysate use and associated water consumption. However, some systems–notably Physidia S3 and, in some configurations, NxStage–rely on packaged dialysate. Producing dialysate bags requires several litres of source water per litre of purified water, plus additional water for plastic manufacture.
https://www.ajkd.org/article/S....0272-6386(25)01168-0

Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis Atrial fibrillation (AF) is common among patients with kidney failure on hemodialysis (KFHD). We studied the outcomes of apixaban initiation, compared with no initiation of any oral anticoagulation (OAC), among patients with KFHD and newly-diagnosed AF.
https://www.ajkd.org/article/S....0272-6386(25)01167-9

Impaired glycolysis-derived serine metabolism as a key driver of podocyte injury with senescence https://www.nature.com/articles/s41467-025-66850-1

Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4 https://www.nature.com/articles/s41598-025-30374-x